AN2 Therapeutics, Inc. (ANTX)
3.55
-0.09
(-2.47%)
USD |
NASDAQ |
Oct 23, 16:00
3.555
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Enterprise Value : 50.51M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 50.51M |
| October 22, 2026 | 53.78M |
| October 21, 2026 | 52.32M |
| October 20, 2026 | 50.87M |
| October 19, 2026 | 43.97M |
| October 16, 2026 | 44.34M |
| October 15, 2026 | 52.32M |
| October 14, 2026 | 50.15M |
| October 13, 2026 | 52.32M |
| October 12, 2026 | 77.74M |
| October 09, 2026 | 81.37M |
| October 08, 2026 | 91.54M |
| October 07, 2026 | 97.71M |
| October 06, 2026 | 105.70M |
| October 05, 2026 | 125.30M |
| October 02, 2026 | 128.94M |
| October 01, 2026 | 125.67M |
| September 30, 2026 | 114.78M |
| September 29, 2026 | 106.42M |
| September 28, 2026 | 103.52M |
| September 25, 2026 | 98.80M |
| September 24, 2026 | 99.16M |
| September 23, 2026 | 96.98M |
| September 22, 2026 | 96.98M |
| September 21, 2026 | 101.70M |
| Date | Value |
|---|---|
| September 18, 2026 | 104.97M |
| September 17, 2026 | 99.53M |
| September 16, 2026 | 115.50M |
| September 15, 2026 | 116.23M |
| September 14, 2026 | 119.86M |
| September 11, 2026 | 118.04M |
| September 10, 2026 | 128.21M |
| September 09, 2026 | 129.66M |
| September 08, 2026 | 138.74M |
| September 04, 2026 | 135.47M |
| September 03, 2026 | 137.65M |
| September 02, 2026 | 137.65M |
| September 01, 2026 | 120.58M |
| August 31, 2026 | 123.13M |
| August 28, 2026 | 124.22M |
| August 27, 2026 | 130.02M |
| August 26, 2026 | 122.40M |
| August 25, 2026 | 127.12M |
| August 24, 2026 | 126.03M |
| August 21, 2026 | 132.57M |
| August 20, 2026 | 131.84M |
| August 19, 2026 | 138.01M |
| August 18, 2026 | 138.38M |
| August 17, 2026 | 129.66M |
| August 14, 2026 | 139.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.20M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -83.01M |
| Fulcrum Therapeutics, Inc. | -32.83M |
| Definium Therapeutics, Inc. | 3.745B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.185M |
| Total Expenses (Quarterly) | 8.185M |
| EPS Diluted (Quarterly) | -0.1829 |
| Earnings Yield | -30.23% |
| Normalized Earnings Yield | -30.23 |